A U.S. FDA clinical trial is now under way to explore the potential of intracorneal inlay technology to correct presbyopia in emmetropic patients.
Unity Biotechnology announces positive data in phase 2 BEHOLD study of UBX1325 in patients with DME
New York ophthalmologists provide eye care in Haiti
FDA approves Coherus’ interchangeable biosimilar for Lucentis
